Heyholder
‹ Activism Filings

Keeps Biopharma Inc. Periodic Report


AI summary · Not investment advice

Keeps Pharma sold KRW 68.4 billion in Q3 but lost KRW 4.98 billion from its main business, turning from profit to loss versus a year earlier.}

Operating profit · 3 months

KRW -5.0 billion

Key facts

Revenue (3 months)
KRW 68.4 billion
Net income (3 months)
KRW -5.2 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 40.9 billion
Revenue (year to date)
KRW 202.8 billion
Operating profit (prior-year 3 months)
KRW 1.4 billion
Operating profit (year to date)
KRW -8.0 billion
Net income (prior-year 3 months)
KRW -446.0 million
Net income (year to date)
KRW -8.6 billion

Commentary

AI commentary · Not investment advice

What happened

Keeps Pharma reported its consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 68.44 billion. That is 67.2% higher than the same 3 months a year earlier (KRW 40.93 billion). It is 8.6% lower than the previous quarter.

In the company's terms

Operating profit (money earned from the core business) for the 3 months was a loss of KRW 4.98 billion. A year earlier, the same period showed a profit of KRW 1.45 billion, so it turned into a loss. Net income (the final profit after taxes and other costs) was a loss of KRW 5.17 billion. A year earlier, the net loss was KRW 0.45 billion.

What changes for shareholders

For the year to date (January 1 to September 30), sales were KRW 202.76 billion. Operating profit was a loss of KRW 8.04 billion. Net income was a loss of KRW 8.60 billion.

Comments

No comments yet

Comments from shareholders will appear here.